News about "Biocon Biologics"

Biocon Launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide in Netherlands

Biocon has launched its GLP-1 drug–device combination, Liraglutide, in the Netherlands, where it will be marketed under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.

Biocon Biologics | 15/12/2025 | By News Bureau

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Biocon Biologics | 08/12/2025 | By Dineshwori

Biocon Biologics Reaches Settlement with Amgen, Secures Market Entry Date for Denosumab Biosimilars

Biocon Biologics will introduce both its Denosumab biosimilars — Vevzuo and Evfraxy — in Europe beginning December 2, 2025. Other terms of the settlement with Amgen remain confidential.

Biocon Biologics | 02/12/2025 | By Dineshwori

US FDA Classifies Biocon Biologics' Bengaluru Drug Substance Facility as VAI

The US FDA has classified Biocon Biologics’ Bengaluru drug substance facility as Voluntary Action Indicated (VAI) following an inspection in August–September 2025. The review covers the site’s production of rh-Insulin and biosimilar Pegfilgrastim for the US market.

Biocon Biologics | 29/11/2025 | By Dineshwori

Biocon Clarifies Media Reports on Possible Biocon Biologics Merger

Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.

Biocon Biologics | 14/11/2025 | By Dineshwori |  176

Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth

Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.

Biocon Biologics | 12/11/2025 | By Dineshwori |  220

Biocon Biologics and Civica Launch Private-Label Insulin Glargine in the US

The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialise under Biocon Biologics’ existing marketing approval.

Biocon Biologics | 21/10/2025 | By Dineshwori |  112

Biocon and Carnegie Secure Tentative FDA Approval for Rifaximin Tablets

Biocon Pharma, a wholly owned subsidiary of Biocon Ltd., in partnership with Carnegie Pharmaceuticals, has received tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg.

Biocon Biologics | 07/10/2025 | By Dineshwori |  208

Biocon Biologics, Amgen Settle Patent Dispute, Paving Way for US Launch of Denosumab Biosimilars

The agreement with Amgen enables Biocon Biologics to launch denosumab biosimilars Bosaya and Aukelso in the US from October 1, 2025.

Biocon Biologics | 01/10/2025 | By Dineshwori |  312

Biocon Biologics Secures US FDA Approval for Denosumab Biosimilars Bosaya and Aukelso

The US Food and Drug Administration (FDA) has approved Biocon Biologics' denosumab biosimilars, Bosaya (denosumab-kyqq) 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection in a single-dose vial, biosimilars of Prolia and Xgeva, respectively.

Biocon Biologics | 17/09/2025 | By Dineshwori |  384